Pfizer ORAL Start Phase 3 study meets primary endpoint
The ongoing two-year study in methotrexate (MTX)-naïve patients with moderate-to-severe active RA, randomized to receive tofacitinib 5mg or 10mg twice-daily (BID) as monotherapy or MTX, met its primary
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.